nitrates has been researched along with Erectile Dysfunction in 45 studies
Nitrates: Inorganic or organic salts and esters of nitric acid. These compounds contain the NO3- radical.
Erectile Dysfunction: The inability in the male to have a PENILE ERECTION due to psychological or organ dysfunction.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The safety of combined administration of ultralow doses of antigens to endothelial NO synthase (impaza) and nitrates for the treatment of erectile dysfunction in CHD patients was evaluated in an open non-comparative clinical trial." | 9.14 | Evaluation of the efficiency and safety of combined treatment with impaza and nitrates in CHD patients with erectile dysfunction. ( Dovgalevskii, PY; Dugina, YL; Epshtein, OI; Kachanova, MV; Sergeeva, SA; Tarasov, SA; Zhavbert, ES, 2009) |
| " To assess whether the metabolic anti-ischemic agent, trimetazidine, is effective in controlling episodes of myocardial ischemia during sexual activity in patients who have CAD and use long-term nitrate therapy, we studied 38 men (57 +/- 6 years of age) who had proved CAD." | 9.11 | Comparison of trimetazidine plus sildenafil to chronic nitrates in the control of myocardial ischemia during sexual activity in patients with coronary artery disease. ( Cerquetani, E; Fini, M; Marazzi, G; Mercuro, G; Patrizi, R; Rosano, GM; Vitale, C; Volterrani, M, 2005) |
| "Aging is associated with erectile dysfunction (ED), in which nitric oxide synthase (NOS) activity and NO bioavailability are reduced due to deficiencies of NOS cofactor (tetrahydrobiopterin, BH(4)) and substrate (L-arginine)." | 7.80 | L-arginine and tetrahydrobiopterin, but not sodium nitrite partially restored erectile dysfunction in aged rats. ( Bayatli, N; Gur, S; Kaya, E; Un, O; Yilmaz, D, 2014) |
| "Oral nitrates were being used by 88 (21%) coronary artery disease patients all of whom were clinically stable." | 7.73 | Successful withdrawal of oral long-acting nitrates to facilitate phosphodiesterase type 5 inhibitor use in stable coronary disease patients with erectile dysfunction. ( Cooper, A; Jackson, G; Martin, E; McGing, E, 2005) |
| "The safety of combined administration of ultralow doses of antigens to endothelial NO synthase (impaza) and nitrates for the treatment of erectile dysfunction in CHD patients was evaluated in an open non-comparative clinical trial." | 5.14 | Evaluation of the efficiency and safety of combined treatment with impaza and nitrates in CHD patients with erectile dysfunction. ( Dovgalevskii, PY; Dugina, YL; Epshtein, OI; Kachanova, MV; Sergeeva, SA; Tarasov, SA; Zhavbert, ES, 2009) |
| " To assess whether the metabolic anti-ischemic agent, trimetazidine, is effective in controlling episodes of myocardial ischemia during sexual activity in patients who have CAD and use long-term nitrate therapy, we studied 38 men (57 +/- 6 years of age) who had proved CAD." | 5.11 | Comparison of trimetazidine plus sildenafil to chronic nitrates in the control of myocardial ischemia during sexual activity in patients with coronary artery disease. ( Cerquetani, E; Fini, M; Marazzi, G; Mercuro, G; Patrizi, R; Rosano, GM; Vitale, C; Volterrani, M, 2005) |
| "Sublingual (SL) apomorphine (2 to 6 mg) has been shown to be effective for treatment of male erectile dysfunction." | 5.09 | Cardiovascular safety of sublingual apomorphine in patients on stable doses of oral antihypertensive agents and nitrates. ( Buttler, S; Edmonds, A; Fagan, TC; Marbury, T; Taylor, A, 2001) |
| "Nitrates and nitrate-containing compounds are vasodilators used for the treatment of angina and heart failure." | 4.98 | A New Perspective on the Nitrate-Phosphodiesterase Type 5 Inhibitor Interaction. ( Goggin, P; Goldstein, I; Hackett, G; Kirby, MG; Kloner, RA; Osterloh, I; Parker, JD; Sadovsky, R, 2018) |
| "Clinical evidence in men with erectile dysfunction (ED) shows that the phosphodiesterase type 5 (PDE5) inhibitors sildenafil citrate, tadalafil, and vardenafil hydrochloride have favorable safety and efficacy profiles." | 4.82 | Pharmacokinetics, pharmacodynamics, and efficacy of phosphodiesterase type 5 inhibitors. ( Sussman, DO, 2004) |
| "Aging is associated with erectile dysfunction (ED), in which nitric oxide synthase (NOS) activity and NO bioavailability are reduced due to deficiencies of NOS cofactor (tetrahydrobiopterin, BH(4)) and substrate (L-arginine)." | 3.80 | L-arginine and tetrahydrobiopterin, but not sodium nitrite partially restored erectile dysfunction in aged rats. ( Bayatli, N; Gur, S; Kaya, E; Un, O; Yilmaz, D, 2014) |
| "We demonstrated that 42% of men with erectile dysfunction who were using nitrates were permitted to discard their nitrates to facilitate sildenafil use, and we identified factors predicting a "no" response to such a request." | 3.74 | Nitrate cessation profiles in men wishing to use sildenafil citrate. ( Guhring, P; Mulhall, JP; Müller, A; Parker, M; Shelton, J, 2007) |
| "Oral nitrates were being used by 88 (21%) coronary artery disease patients all of whom were clinically stable." | 3.73 | Successful withdrawal of oral long-acting nitrates to facilitate phosphodiesterase type 5 inhibitor use in stable coronary disease patients with erectile dysfunction. ( Cooper, A; Jackson, G; Martin, E; McGing, E, 2005) |
| " After a 10- to 21-day washout period, subjects crossed over to either placebo or tadalafil, and nitrate dosing was repeated." | 2.71 | Time course of the interaction between tadalafil and nitrates. ( Denne, J; Emmick, JT; Hutter, AM; Jackson, G; Kloner, RA; Mitchell, MI, 2003) |
| " Once it is clear to the patients that erectile dysfunction can be satisfactorily overcome, the long-term use of treatments to do so tends to wane." | 2.41 | Non-surgical management of erectile dysfunction. ( Crowley, T; Gingell, C; Levy, A, 2000) |
| "Erectile dysfunction is a common problem affecting men." | 2.40 | Use of oral sildenafil (Viagra) in the treatment of erectile dysfunction. ( Licht, MR, 1999) |
| "Two composite outcomes were measured: 1) cardiac arrest, shock, myocardial infarction, ischemic stroke, or acute coronary arteriography and 2) syncope, angina pectoris, or drug-related adverse event." | 1.72 | Adverse Events Associated With Coprescription of Phosphodiesterase Type 5 Inhibitors and Oral Organic Nitrates in Male Patients With Ischemic Heart Disease : A Case-Crossover Study. ( Blanche, P; El-Sheikh, M; Gislason, G; Holt, A; Jensen, AKG; Jensen, MH; Lamberts, M; McGettigan, P; Nouhravesh, N; Rajan, D; Schjerning, AM; Schou, M; Torp-Pedersen, C, 2022) |
| "Dyslipidemia was showed by 52." | 1.48 | Relationship Between Erectile Dysfunction, Diabetes and Dyslipidemia in Hypertensive-Treated Men. ( Lahera, V; Lopez-Farre, AJ; Prieto, R; Puigvert, A; Rodriguez-Pardo, JM; Segura, A; Zamorano-Leon, JJ, 2018) |
| " The phosphodiesterase type 5 inhibitors (PDE5-i): sildenafil, taldalafil, vardenafil, and avanafil are EMA European Medicines Agency approved and show similar adverse events and success rates." | 1.46 | [Side effects of erectile dysfunction drug treatment]. ( Sperling, H, 2017) |
| "In the modern era of pharmacologic treatment of erectile dysfunction, men with heart disease increasingly approach their physicians regarding the possibility of restoring sexual activity." | 1.33 | Sex, the heart, and heart failure. ( Brunner, H; Kiowski, W; Schalcher, C, 2006) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 12 (26.67) | 18.2507 |
| 2000's | 22 (48.89) | 29.6817 |
| 2010's | 8 (17.78) | 24.3611 |
| 2020's | 3 (6.67) | 2.80 |
| Authors | Studies |
|---|---|
| Holt, A | 1 |
| Blanche, P | 1 |
| Jensen, AKG | 1 |
| Nouhravesh, N | 1 |
| Rajan, D | 1 |
| Jensen, MH | 1 |
| El-Sheikh, M | 1 |
| Schjerning, AM | 1 |
| Schou, M | 1 |
| Gislason, G | 1 |
| Torp-Pedersen, C | 1 |
| McGettigan, P | 1 |
| Lamberts, M | 1 |
| Nunes, AP | 1 |
| Seeger, JD | 1 |
| Stewart, A | 1 |
| Gupta, A | 1 |
| McGraw, T | 1 |
| Zamorano-Leon, JJ | 1 |
| Segura, A | 1 |
| Lahera, V | 1 |
| Rodriguez-Pardo, JM | 1 |
| Prieto, R | 1 |
| Puigvert, A | 1 |
| Lopez-Farre, AJ | 1 |
| Kloner, RA | 3 |
| Goggin, P | 1 |
| Goldstein, I | 1 |
| Hackett, G | 1 |
| Kirby, MG | 1 |
| Osterloh, I | 1 |
| Parker, JD | 1 |
| Sadovsky, R | 1 |
| Un, O | 1 |
| Yilmaz, D | 1 |
| Bayatli, N | 1 |
| Kaya, E | 1 |
| Gur, S | 1 |
| Sperling, H | 1 |
| Girardin, F | 1 |
| Berney, P | 1 |
| Schulz, P | 1 |
| Zhavbert, ES | 1 |
| Kachanova, MV | 1 |
| Tarasov, SA | 1 |
| Dugina, YL | 1 |
| Sergeeva, SA | 1 |
| Dovgalevskii, PY | 1 |
| Epshtein, OI | 1 |
| Chang, LL | 1 |
| Ma, M | 1 |
| Allmen, Hv | 1 |
| Henderson, SC | 1 |
| Harper, K | 1 |
| Hornbuckle, K | 1 |
| Roegler, C | 1 |
| Lehmann, J | 1 |
| Ude, M | 1 |
| Ude, C | 1 |
| Leuner, K | 1 |
| Javaroni, V | 1 |
| Queiroz Miguez, M | 1 |
| Burla, A | 1 |
| Oigman, W | 1 |
| Neves, MF | 1 |
| Bivalacqua, TJ | 1 |
| Usta, MF | 1 |
| Champion, HC | 1 |
| Adams, D | 1 |
| Namara, DB | 1 |
| Abdel-Mageed, AB | 1 |
| Kadowitz, PJ | 1 |
| Hellstrom, WJ | 1 |
| Tuncayengin, A | 1 |
| Biri, H | 1 |
| Onaran, M | 1 |
| Sen, I | 1 |
| Tuncayengin, O | 1 |
| Polat, F | 1 |
| Erbaş, D | 1 |
| Bozkirli, I | 1 |
| Iglesias, ML | 1 |
| Jericó, C | 1 |
| Skaf, E | 1 |
| Pedro-Botet, J | 1 |
| Hutter, AM | 2 |
| Emmick, JT | 1 |
| Mitchell, MI | 1 |
| Denne, J | 1 |
| Jackson, G | 2 |
| Edmunds-Ogbuokiri, T | 1 |
| Sussman, DO | 1 |
| Rosano, GM | 1 |
| Marazzi, G | 1 |
| Patrizi, R | 1 |
| Cerquetani, E | 1 |
| Vitale, C | 1 |
| Volterrani, M | 1 |
| Fini, M | 1 |
| Mercuro, G | 1 |
| Hogan, MJ | 1 |
| Martin, E | 1 |
| McGing, E | 1 |
| Cooper, A | 1 |
| Kiowski, W | 1 |
| Brunner, H | 1 |
| Schalcher, C | 1 |
| Müller, A | 1 |
| Shelton, J | 1 |
| Parker, M | 1 |
| Guhring, P | 1 |
| Mulhall, JP | 2 |
| Conti, CR | 1 |
| Billner, KL | 1 |
| Maisch, B | 1 |
| Lycklama à Nijeholt, AA | 1 |
| Licht, MR | 1 |
| Ishikura, F | 1 |
| Manecke, RG | 1 |
| Levy, A | 1 |
| Crowley, T | 1 |
| Gingell, C | 1 |
| Biron, CR | 1 |
| Williams, D | 1 |
| Feely, J | 1 |
| James, JS | 1 |
| Howes, L | 1 |
| Fagan, TC | 1 |
| Buttler, S | 1 |
| Marbury, T | 1 |
| Taylor, A | 1 |
| Edmonds, A | 1 |
9 reviews available for nitrates and Erectile Dysfunction
| Article | Year |
|---|---|
A New Perspective on the Nitrate-Phosphodiesterase Type 5 Inhibitor Interaction.
Topics: Angina Pectoris; Animals; Blood Pressure; Contraindications, Drug; Drug Interactions; Erectile Dysfu | 2018 |
[Medicinal chemistry of nitrates and PDE5 inhibitors].
Topics: Endothelium-Dependent Relaxing Factors; Erectile Dysfunction; Humans; Male; Models, Molecular; Nitra | 2010 |
[Nitrates and PDE5 inhibitors: pharmaceutical care].
Topics: Erectile Dysfunction; Humans; Male; Nitrates; Pharmaceutical Services; Pharmacies; Phosphodiesterase | 2010 |
Pharmacokinetics, pharmacodynamics, and efficacy of phosphodiesterase type 5 inhibitors.
Topics: Antihypertensive Agents; Cardiovascular Diseases; Diabetes Complications; Drug Interactions; Erectil | 2004 |
Erectile dysfunction and sildenafil.
Topics: Drug Interactions; Enzyme Inhibitors; Erectile Dysfunction; Female; Humans; Nitrates; Piperazines; P | 1998 |
Use of oral sildenafil (Viagra) in the treatment of erectile dysfunction.
Topics: Clinical Trials as Topic; Contraindications; Drug Synergism; Erectile Dysfunction; Humans; Hypotensi | 1999 |
Medical treatment of erectile dysfunction.
Topics: Adrenergic alpha-Antagonists; Aged; Alprostadil; Clinical Trials as Topic; Dopamine Agonists; Drug I | 1999 |
Non-surgical management of erectile dysfunction.
Topics: Administration, Topical; Alprostadil; Erectile Dysfunction; Humans; Male; Middle Aged; Nitrates; Pen | 2000 |
Sex and the patient with cardiovascular risk factors: focus on sildenafil.
Topics: Antihypertensive Agents; Contraindications; Drug Synergism; Erectile Dysfunction; Humans; Male; Myoc | 2000 |
5 trials available for nitrates and Erectile Dysfunction
| Article | Year |
|---|---|
Evaluation of the efficiency and safety of combined treatment with impaza and nitrates in CHD patients with erectile dysfunction.
Topics: Antibodies; Coronary Disease; Erectile Dysfunction; Humans; Male; Middle Aged; Nitrates; Treatment O | 2009 |
Response to on-demand vardenafil was improved by its daily usage in hypertensive men.
Topics: Aged; Blood Glucose; Brachial Artery; Carotid Intima-Media Thickness; Cholesterol, LDL; Erectile Dys | 2012 |
Time course of the interaction between tadalafil and nitrates.
Topics: Adult; Aged; Aged, 80 and over; Angina Pectoris; Carbolines; Contraindications; Cross-Over Studies; | 2003 |
Comparison of trimetazidine plus sildenafil to chronic nitrates in the control of myocardial ischemia during sexual activity in patients with coronary artery disease.
Topics: Adult; Aged; Analysis of Variance; Coitus; Cross-Over Studies; Double-Blind Method; Drug Therapy, Co | 2005 |
Cardiovascular safety of sublingual apomorphine in patients on stable doses of oral antihypertensive agents and nitrates.
Topics: Administration, Sublingual; Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Adult; Aged; | 2001 |
31 other studies available for nitrates and Erectile Dysfunction
| Article | Year |
|---|---|
Summary for Patients: Risk for Unwanted Outcomes in Men Prescribed Both Drugs for Erectile Dysfunction and Nitrates for Angina.
Topics: Angina Pectoris; Erectile Dysfunction; Humans; Male; Nitrates; Vasodilator Agents | 2022 |
Adverse Events Associated With Coprescription of Phosphodiesterase Type 5 Inhibitors and Oral Organic Nitrates in Male Patients With Ischemic Heart Disease : A Case-Crossover Study.
Topics: Cross-Over Studies; Erectile Dysfunction; Humans; Male; Myocardial Ischemia; Nitrates; Phosphodieste | 2022 |
Cardiovascular Outcome Risks in Patients With Erectile Dysfunction Co-Prescribed a Phosphodiesterase Type 5 Inhibitor (PDE5i) and a Nitrate: A Retrospective Observational Study Using Electronic Health Record Data in the United States.
Topics: Adult; Electronic Health Records; Erectile Dysfunction; Humans; Male; Nitrates; Phosphodiesterase 5 | 2021 |
Relationship Between Erectile Dysfunction, Diabetes and Dyslipidemia in Hypertensive-Treated Men.
Topics: Age Factors; Comorbidity; Diabetes Mellitus; Dyslipidemias; Erectile Dysfunction; Humans; Hypertensi | 2018 |
L-arginine and tetrahydrobiopterin, but not sodium nitrite partially restored erectile dysfunction in aged rats.
Topics: Aging; Animals; Arginine; Biopterins; Dose-Response Relationship, Drug; Erectile Dysfunction; Male; | 2014 |
[Side effects of erectile dysfunction drug treatment].
Topics: Contraindications, Drug; Drug Therapy, Combination; Erectile Dysfunction; Evidence-Based Medicine; G | 2017 |
An early report on the role of nitrates in erectile dysfunction.
Topics: Erectile Dysfunction; Humans; Male; Middle Aged; Nitrates; Penile Erection; Vasodilator Agents | 2009 |
Co-possession of phosphodiesterase type-5 inhibitors (PDE5-I) with nitrates.
Topics: Adolescent; Adult; Aged; Carbolines; Databases, Factual; Drug Therapy, Combination; Erectile Dysfunc | 2010 |
Gene transfer of endothelial nitric oxide synthase partially restores nitric oxide synthesis and erectile function in streptozotocin diabetic rats.
Topics: Animals; beta-Galactosidase; Diabetes Mellitus, Experimental; Erectile Dysfunction; Gene Transfer Te | 2003 |
Cavernosal tissue nitrite, nitrate, malondialdehyde and glutathione levels in diabetic and non-diabetic erectile dysfunction.
Topics: Adult; Aged; Diabetes Complications; Erectile Dysfunction; Glutathione; Humans; Male; Malondialdehyd | 2003 |
Sildenafil and coronary artery disease.
Topics: Contraindications; Erectile Dysfunction; Humans; Hypercholesterolemia; Male; Middle Aged; Myocardial | 2003 |
Ritonavir increases levels of erectile dysfunction agent 49 fold.
Topics: Adrenergic alpha-Antagonists; Drug Interactions; Erectile Dysfunction; HIV Protease Inhibitors; Huma | 2004 |
Erectile dysfunction and cardiovascular considerations: managing patients effectively with phosphodiesterase type 5 inhibitors.
Topics: 3',5'-Cyclic-GMP Phosphodiesterases; Cardiovascular Diseases; Contraindications; Cyclic Nucleotide P | 2004 |
My doctor prescribed Cialis [tadalafil] for erectile dysfunction. Anything I need to watch out for? I have a heart condition.
Topics: Adrenergic alpha-Antagonists; Carbolines; Contraindications; Drug Interactions; Erectile Dysfunction | 2004 |
Erectile dysfunction and cardiovascular disease.
Topics: Adrenergic Antagonists; Carbolines; Cardiovascular Diseases; Contraindications; Erectile Dysfunction | 2005 |
Successful withdrawal of oral long-acting nitrates to facilitate phosphodiesterase type 5 inhibitor use in stable coronary disease patients with erectile dysfunction.
Topics: Administration, Oral; Aged; Contraindications; Coronary Artery Disease; Drug Interactions; Erectile | 2005 |
Sex, the heart, and heart failure.
Topics: 3',5'-Cyclic-GMP Phosphodiesterases; Cardiovascular Diseases; Contraindications; Erectile Dysfunctio | 2006 |
Nitrate cessation profiles in men wishing to use sildenafil citrate.
Topics: Adult; Age Factors; Aged; Cohort Studies; Confidence Intervals; Drug Interactions; Erectile Dysfunct | 2007 |
Viagra, the latest cardio-VASCULAR drug.
Topics: Cardiovascular System; Contraindications; Drug Interactions; Enzyme Inhibitors; Erectile Dysfunction | 1998 |
Viagra: beyond the jokes.
Topics: Cyclic GMP; Drug Interactions; Erectile Dysfunction; Humans; Hypotension; Male; Nitrates; Phosphodie | 1998 |
[Therapy recommendations for adverse effects of Viagra and nitrates (NO-donors)].
Topics: Angina Pectoris; Blood Pressure; Contraindications; Drug Therapy, Combination; Erectile Dysfunction; | 1998 |
[The erection pill].
Topics: Adult; Age Factors; Aged; Cardiovascular Diseases; Contraindications; Drug Interactions; Erectile Dy | 1998 |
Viagra: how safe is the new 'sex pill'?
Topics: Drug Interactions; Enzyme Inhibitors; Erectile Dysfunction; Female; Humans; Male; Nitrates; Nitric O | 1998 |
A statement on the use of sildenafil in the management of sexual dysfunction in patients with cardiovascular disease. Heart and Stroke Foundation of Canada. Canadian Cardiovascular Society.
Topics: Cardiovascular Diseases; Contraindications; Decision Trees; Erectile Dysfunction; Humans; Male; Nitr | 1999 |
[Viagra landing: the dawn of sexual science in cardiology].
Topics: 3',5'-Cyclic-GMP Phosphodiesterases; Coronary Disease; Drug Synergism; Erectile Dysfunction; Humans; | 1999 |
Managing sexual dysfunction. Using sildenafil for patients with cardiovascular disease. Heart and Stroke Foundation of Canada. Canadian Cardiovascular Society.
Topics: Cardiovascular Diseases; Contraindications; Erectile Dysfunction; Humans; Hypotension; Male; Nitrate | 2000 |
Viagra presents special concerns for the hygienist and the dental team.
Topics: Chest Pain; Contraindications; Dental Care; Drug Interactions; Erectile Dysfunction; Humans; Hypoten | 1998 |
Initial uptake in use of sildenafil in general practice.
Topics: Adolescent; Adult; Aged; Drug Interactions; Erectile Dysfunction; Family Practice; Humans; Ireland; | 2001 |
Viagra: new warning with protease inhibitors.
Topics: Drug Interactions; Erectile Dysfunction; HIV Infections; HIV Protease Inhibitors; Humans; Male; Nitr | 1999 |
Diltiazem-mediated inhibition of sildenafil metabolism may promote nitrate-induced hypotension.
Topics: Aged; Cardiac Catheterization; Cardiovascular Agents; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzym | 2001 |
[Erectile dysfunction. Help also for cardiac patients].
Topics: Apomorphine; Contraindications; Coronary Disease; Drug Interactions; Erectile Dysfunction; Humans; M | 2001 |